Prophylactic Management of IRRs With Amivantamab Plus Lazertinib for NSCLC
Panelists discuss other adverse events associated with amivantamab and lazertinib beyond infusion-related reactions.
Related Articles
Cilta-Cel Shows ‘Promising Efficacy, Safety’ in Newly Diagnosed MM | Blood Cancers Today
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM who have had suboptimal response to frontline…
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma
Jeffrey Graham University of Manitoba Ardalan E. Ahmad University of Manitoba Naveen S. Basappa University of Alberta Jean-Christophe Bernhard CHU de Bordeaux, France Bimal Bhindi…
Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis
A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.
A mom’s journey is a sign of hope for starting a family after cancer treatment
Little Penelope Lo Destro’s parents were about to start their family when there was a terrible diagnosis.
Erba Explores myeloMATCH Substudies Targeting Genetic Diversity in AML, MDS
Harry Erba, MD, PhD, discusses the specific substudies included in myeloMATCH.
Palliative Approach to Care an Untapped Benefit for Patients With Multiple Myeloma – Oncology Nurse Advisor
Researchers sought to better understand the experiences of patients living with multiple myeloma and their perceptions of palliative care.
Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma
Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma
Jeffrey Graham University of Manitoba Ardalan E. Ahmad University of Manitoba Naveen S. Basappa University of Alberta Jean-Christophe Bernhard CHU de Bordeaux, France Bimal Bhindi…
When It’s OK to Trust Your Gut on a Big Decision
Should you use your gut feel or not? Recent research suggests that it can be useful, especially in highly uncertain circumstances where further data gathering…
FDA Approves Attruby™ (acoramidis) for the Treatment of ATTR-CM: A New Option for Patients
The FDA’s approval of Attruby is significant for patients with ATTR-CM, providing them with another effective treatment option.
